AMAG Pharma (AMAG) Reports Q4 Loss of $0.31

AMAG Pharma (NASDAQ: AMAG) reported Q4 EPS of ($0.31), versus $0.20 reported last year. Revenue for the quarter came in at $151.6 million versus the consensus estimate of $153.25 million.

"We drove significant top- and bottom-line growth in 2016, building an even stronger base to grow and expand upon in 2017,” said William Heiden, AMAG’s chief executive officer. “We achieved our 2016 financial goals with strong performance across each of our products, generated significant cash flows, and advanced our next-generation development programs. In addition to the revenue growth announced today from our current marketed product portfolio, we recently expanded our women's health portfolio, acquiring rights to RekyndaTM and IntrarosaTM, two important products with long-term growth potential. In 2017, we expect to continue to drive growth across our portfolio, execute well on upcoming new product launches, and continue to expand our product portfolio through additional business development transactions

For earnings history and earnings-related data on AMAG Pharma (AMAG) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Eltek Ltd (ELTK) Reports Q2 EPS of $0.41
• Prenetics Global (PRE) Tops Q2 EPS by 18c